nCage Therapeutics Joins the World Vaccine Congress Europe and Continued Progress on a First-In-Class Universal Flu Vaccine

Krakow, Poland – November 5, 2026 – nCage Therapeutics joined the World Vaccine Congress Europe, held October 19–21, 2026 at the RAI Convention Center in Amsterdam, Netherlands. A key area of focus at this year's congress was the continued need to explore novel new platform technologies that can advance vaccine development. nCage platform received considerable interest given their programmable protein scaffolds provide for the development of next generation synthetic VLP vaccines and protein drug conjugates (PDCs).

nCage also had the opportunity to share progress in the pre-clinical development of its first-in-class Universal Flu vaccine. The program is being carried out in collaboration with the University of Oxford UK, under an exclusive license to develop Oxford epitope technology, and combines nCage's proprietary antigen design with the nCage TRAP-cage platform to deliver broad and durable protection against influenza.

Recent data on seasonal influenza vaccines demonstrate limited efficacy and short-lived protection, and currently available products must be reformulated every year. An innovative vaccine that protects against diverse flu strains over multiple seasons would address a major unmet clinical need.

John Bason, CEO of nCage, said: “A universal flu vaccine that protects across strains and seasons will remove the need for annual reformulation and provides patients an opportunity to be vaccinated in a single injection that provides multi-year coverage. Our collaboration with Oxford brings together their antigen design and our TRAP-cage platform, and we are extremely encouraged by the early pre-clinical results.”